Table 2.

The severity of nonalcoholic fatty liver disease in relation to cardiovascular outcomes in patients with different BP status.

	Events/subjects (6045/71926)	HR (95% CI)
		Crude model	P value	Model 1	P value	Model 2	P value
Normal blood pressure
Nonfatty liver	(399/12108)	Reference		Reference		Reference
Mild NAFLD	(89/1801)	1.560 (1.234–1.972)	<0.001	1.299 (1.026–1.645)	0.030	1.129 (0895–1.423)	0.305
Moderate/Severe NAFLD	(32/588)	1.601 (1.097–2.368)	0.015	1.309 (0.895–1.913)	0.165	1.177 (0.819–1.423)	0.379
Prehypertension
Nonfatty liver	(977/18728)	1.625 (1.441–1.833)	<0.001	1.247 (1.105–1.408)	<0.001	1.189 (1.057–1.337)	0.004
Mild NAFLD	(302/4670)	2.073 (1.779–2.417)	<0.001	1.487 (1.272–1.738)	<0.001	1.251 (1.072–1.458)	0.004
Moderate/Severe NAFLD	(168/2035)	2.654 (2.207–3.192)	<0.001	1.931 (1.599–2.332)	<0.001	1.558 (1.293–1.877)	<0.001
Hypertension
Nonfatty liver	(2192/18535)	3.901 (3.493–4.357)	<0.001	2.243 (2.002–2.513)	<0.001	2.086 (1.869–2.330)	<0.001
Mild NAFLD	(1114/8125)	4.580 (4.069–5.155)	<0.001	2.761 (2.439–3.126)	<0.001	2.304 (2.039–2.603)	<0.001
Moderate/Severe NAFLD	(772/5336)	4.837 (4.268–5.482)	<0.001	2.942 (2.574–3.363)	<0.001	2.357 (2.063–2.691)	<0.001
P for trend		<0.001		<0.001		<0.001

HR, hazard ratio; NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; FBG, fasting blood glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HsCRP, high-sensitivity C-reactive protein; TG, triglyceride; eGFR, estimated glomerular filtration rate. Model 1 was adjusted for age, sex, physical activity, BMI (≥30, 25–29.9, 18.5–24.9, <18.5), smoke. Model 2 was adjusted for age, sex, physical activity, education, BMI (≥30, 25–29.9, 18.5–24.9, <18.5), smoke, FBG, antidiabetic medication, lipid-lowering medication, TG, LDL, HDL, HsCRP and eGFR.